RedHill Biopharma Ltd. RDHL
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a GI/hepatology drug developer. Its lead program, Talicia (omeprazole, amoxicillin, rifabutin), is in Phase 2 for H. pylori infection.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Talicia | H. pylori infection (US marketed with Cumberland; ex-US out-licensed) | small molecule | Approved |
| RHB-102 (Bekinda, bimodal ondansetron) | Oncology support, gastritis/gastroenteritis, IBS-D, GLP-1/GIP-associated GI intolerance | small molecule | Phase 2 |
| Opaganib | Cancers (prostate, cholangiocarcinoma, CLL), viral ARDS, metabolic disorders, radiation protection | small molecule | Phase 2 |
| RHB-107 (upamostat) | COVID-19 and other viruses; oncology | small molecule | Phase 2 |
| RHB-104 | Crohn's disease / multiple sclerosis | small molecule | Phase 2 |
| RHB-204 | Nontuberculous mycobacterial (NTM) infections | small molecule | Phase 2 |
Recent results and decisions
- Nov 2, 2026positive Two leading labs confirm RHB-204's MAP-killing capability and comparability to RHB-104 in in vitro studies.
In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to RedHill's RHB-104 in both long-term intracellular culture and spot and phage assays
Filing - Nov 2, 2026met RHB-104 met the primary endpoint in its Phase 3 study, demonstrating 64% greater effectiveness than standard of care alone in treating Crohn's disease (p=0.0048).
RHB-104 met the primary endpoint with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone in treating Crohn's disease, compared to the placebo (standard of care only) group (p = 0.0048).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.